Skip to main content
. 2022 Aug 17;195(3):333–340. doi: 10.1007/s10549-022-06703-3

Table 1.

Patient and disease characteristics

Variable Total cohort (n = 72) Neratinib monotherapy n = 27) Neratinib with capecitabine (n = 45)
n (%) n (%) n (%)
Age
  < 65 58 (81) 19 (70) 39 (87)
  ≥ 65 14 (19) 8 (30) 6 (13)
ECOG Performance status
 0 15 (21) 3 (11) 12 (27)
 1 49 (68) 19 (70) 30 (67)
 2 6 (8) 3 (11) 3 (7)
 3 2 (3) 2 (7) 0 (0)
Cutaneous disease
 Yes 14 (19) 6 (22) 8 (18)
Bone
 Yes 46 (64) 17 (63) 29 (64)
Visceral
 Yes 53 (74) 21 (78) 32 (71)
Brain metastasis
 Yes 38 (53) 15 (56) 18 (40)
Leptomeningeal disease
 Yes 7 (10) 5 (19) 4 (9)
Measurable disease
 Yes 63 (88) 23 (85) 40 (89)
Histology
 IDC 61 (85) 25 (93) 36 (80)
 ILC 6 (8) 2 (7) 4 (9)
 Mixed IDC/ILC 2 (3) 0 (0) 2 (4)
 Unknown 3 (4) 0 (0) 3 (7)
Grade
 1 2 (3) 1 (4) 1 (2)
 2 19 (26) 8 (30) 11 (24)
 3 48 (67) 18 (67) 40 (89)
 Unknown 3 (4) 0 (0) 3 (7)
ER status
 Negative 29 (40) 11 (41) 18 (40)
 Positive 42 (58) 16 (59) 26 (58)
 Unknown 1 (1) 0 (0) 1 (2)
 ER Allred score: median (IQR), (range) 6 (0–8), (0–8) 7 (0–8), (0–8) 5 (0–8), (0–8)
PgR status
 Negative 37 (51) 12 (44) 25 (56)
 Positive 26 (36) 12 (44) 14 (31)
 Unknown 9 (13) 3 (11) 6 (13)
 PgR Allred score: median (IQR), (range) 0 (0–5), (0–8) 1 (0–5), (0–8) 1 (0–4), (0–8)
HER2 status
 IHC3 +  58 (81) 22 (81) 36 (80)
 IHC2 + /ISH+ 11 (15) 3 (11) 8 (18)
 HER2 Positive but IHC unknown 3 (4) 2 (7) 1 (2)
 Prior lines of treatment: median (IQR), (range) 3 (2–4) (1–7) 3 (3–5), (1–7) 2 (2–3), (1–6)
Prior anti-HER2 TKI
 Yes 22 (31) 13 (48) 9 (20)
Prior pertuzumab
 Yes 35 (49) 12 (44) 23 (51)
Prior T-DM1
 Yes 62 (86) 24 (89) 38 (84)
 Prior  Fulvestrant 4 (6) 4 (15) 0 (0)
 Prior Trastuzumab 3(6) 2 (7) 1 (2)

IDC Invasive ductal carcinoma, ILC Invasive lobular carcinoma